When compared the studied miRNAs and the predicted target PG molecules with controls, we found serum PGA levels in GC patients were decreased (130.1 ± 107.1 vs. 146.3 ± 101.5, p = 0.276), and PGC levels in GC patients were increased (23.1 ± 23.0 vs. 19.2 ± 17.6 p = 0.174), though the differences were not significant. The gene discussed is PGC; the disease is gastric cancer.